|Over a week ago|
Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities » 10:1001/1501/15/21
B. Riley Securities…
B. Riley Securities analyst Mayank Mamtani downgraded Arcturus Therapeutics (ARCT) to Neutral from Buy with a price target of $77, down from $138, after Johnson & Johnson (JNJ) released what Mamtani called "compelling" Phase I/II immunogenicity data on its COVID-19 vaccine candidate, Ad26. J&J's data exceeded Street expectations, particularly on neutralizing antibody responses, according to Mamtani, who thinks the results raise the uncertainty about ARCT-021's path to "being a formidable C-19 vaccine player."
Arcturus Therapeutics call volume above normal and directionally bullish » 13:0501/0801/08/21
Bullish option flow…
Bullish option flow detected in Arcturus Therapeutics with 16,904 calls trading, 6x expected, and implied vol increasing almost 21 points to 139.03%. Feb-21 60 calls and Jan-21 55 calls are the most active options, with total volume in those strikes near 4,400 contracts. The Put/Call Ratio is 0.19. Earnings are expected on March 11th.
Arcturus Therapeutics call volume above normal and directionally bullish » 14:4501/0701/07/21
Bullish option flow…
Bullish option flow detected in Arcturus Therapeutics with 17,453 calls trading, 6x expected, and implied vol increasing over 6 points to 121.15%. Jan-21 70 calls and Jan-21 60 calls are the most active options, with total volume in those strikes near 5,000 contracts. The Put/Call Ratio is 0.24. Earnings are expected on March 11th.
Fly Intel: Top five analyst initiations » 09:5601/0701/07/21
ARCT, MGTA, ARAY, NOG, KNOP
Catch up on today's…
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Arcturus Therapeutics (ARCT) initiated with an Overweight at Wells Fargo. 2. Magenta Therapeutics (MGTA) initiated with a Buy at Mizuho. 3. Accuray (ARAY) initiated with an Outperform at Northland. 4. Northern Oil and Gas (NOG) initiated with a Strong Buy at Raymond James. 5. Knot Offshore Partners (KNOP) initiated with Buy at B. Riley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Arcturus Therapeutics initiated with an Overweight at Wells Fargo » 06:2401/0701/07/21
Wells Fargo analyst Jim…
Wells Fargo analyst Jim Birchenough initiated coverage of Arcturus Therapeutics with an Overweight rating and $118 price target. Birchenough believes that Arcturus has validated the potential value and differentiation of its self-amplifying mRNA delivery through novel lipid nanoparticle suspension and is poised for success with its lead mRNA vaccine ARCT-021 and sees a window for ARCT-021 to achieve competitive data with a superior dose form and drive significant value.
Arcturus Therapeutics call volume above normal and directionally bullish » 13:4501/0401/04/21
Bullish option flow…
Bullish option flow detected in Arcturus Therapeutics with 7,870 calls trading, 3x expected, and implied vol increasing almost 5 points to 125.33%. Jan-21 50 calls and Jan-21 75 calls are the most active options, with total volume in those strikes near 2,600 contracts. The Put/Call Ratio is 0.12. Earnings are expected on March 11th.
Fly Intel: Pre-market Movers » 09:0901/0401/04/21
TSLA, FLIR, MGLN, NCTY, HLF, VRAY, ARCT, ALSK, GT, GNW, AI, TDY, CNC
Check out this morning's…
Arcturus Therapeutics receives FDA allowance to proceed with ARCT-021 study » 07:1201/0401/04/21
Arcturus Therapeutics announced that the company has received allowance of the investigational new drug, or IND, application from the FDA for the Phase 2 clinical study of its vaccine candidate ARCT-021 following review of data from the Phase 1/2 study. The Phase 2 study will enroll 600 participants, with 450 receiving ARCT-021 and 150 receiving placebo. Both older and younger adult participants will be included. Early interim analyses of safety and immunogenicity will be performed to inform dose selection for a Phase 3 study, which is targeted to start in Q2, if the Phase 2 study is successful.
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg » 07:1812/3112/31/20
ARCT, MRNA, PFE
Ladenburg analyst Wangzhi…
Ladenburg analyst Wangzhi Li said that a UK study of 2,826 healthcare and frontline workers with high exposure risk to COVID-19 shows "strong evidence" that T cell response alone in seronegative subjects could achieve complete protection from COVID-19 without antibody response, which the analyst points to as support for the view that there is a "good probability" that Arcturus Therapeutics' (ARCT) ARCT-021 can ultimately achieve "90+% protection efficacy" despite the latest ARCT-021 data update that raised questions about a lower titer of neutralizing antibody response. The analyst, who still sees a good probability for ARCT-021 to achieve efficacy close to that seen with the vaccines from Moderna (MRNA) and Pfizer (PFE), keeps a Buy rating and $123 price target on Arcturus shares.
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform » 11:0312/3012/30/20
After Arcturus announced…
After Arcturus announced this morning its selection of a therapeutic candidate, ARCT-032, for the LUNAR-CF program, Piper Sandler analyst Yasmeen Rahimi noted that "bears may view this morning's announcement as a distraction from ARCT-021's COVID-19 program." However, Rahimi thinks the market has been "overreacting" to the neutralizing titer data from ARCT-021's Phase 1 update and continues to "strongly believe" in the company's mRNA technology platform, the analyst tells investors. Rahimi has an Overweight rating and $140 price target on Arcturus shares.